{
  "prompt": {
    "prompt": "Original Transcript:\nSITUATION: 25-year-old G1P0 at 12+3 weeks gestation presenting with excessive nausea, vomiting, and suspected molar pregnancy\n\nBACKGROUND: Miss Adams has experienced severe hyperemesis since 8 weeks gestation, significantly worse than typical morning sickness described by friends. She reports vomiting 15-20 times daily, unable to keep down solid food for 2 weeks, and has lost 6kg since pregnancy confirmation. She also noticed vaginal spotting for 3 days, initially light pink but now brown discharge. Her symptoms seem disproportionately severe for gestational age. Last menstrual period was 13 weeks ago, home pregnancy tests have been consistently strongly positive. No previous pregnancies, conceived naturally after 4 months of trying. Family history includes thyroid disease (maternal). She appears significantly dehydrated and has been unable to work for 1 week due to severity of symptoms.\n\nASSESSMENT: Patient appears dehydrated and unwell, with obvious weight loss. Vital signs: BP 108/68 mmHg, HR 102 bpm, temp 36.9°C. Weight 52kg (down from 58kg at GP booking). Thyrotoxic signs present: mild tremor, warm skin, tachycardia. Abdominal examination reveals uterine size larger than expected for dates (approximately 16-week size). Speculum shows brown discharge from cervical os, no active bleeding. Transvaginal ultrasound demonstrates characteristic 'snowstorm' appearance with multiple cystic spaces throughout uterine cavity, no fetal pole visible. Quantitative β-hCG markedly elevated at 186,000 mIU/mL (much higher than expected for gestational age). Thyroid function tests show suppressed TSH <0.1 mU/L, elevated free T4 28 pmol/L indicating gestational thyrotoxicosis. Chest X-ray clear, no evidence of pulmonary metastases.\n\nRECOMMENDATION: Diagnosis of complete hydatidiform mole requiring urgent evacuation. Pre-operative investigations including FBC, coagulation screen, cross-match for 2 units blood. Surgical evacuation arranged urgently via suction curettage under general anesthetic. IV fluid resuscitation commenced. Antiemetics for symptom control. Propranolol considered for thyrotoxicosis symptoms. Post-evacuation histology confirmation and registration with regional trophoblastic screening center mandatory. Serial β-hCG monitoring weekly until negative then monthly for 6 months. Reliable contraception essential during follow-up period. Patient counseled regarding excellent prognosis with appropriate follow-up and monitoring.\n\nGuideline Analysis:\n### Management of Gestational Trophoblastic Disease\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document whether Anti-D prophylaxis was given (if the patient is Rh-negative).  \n   Reason: The guideline recommends Anti-D prophylaxis following removal of a molar pregnancy to prevent Rh sensitization in future pregnancies.  \n\n2. **Different management plan** - Ensure oxytocic infusion is **not** used prior to completion of surgical evacuation unless significant hemorrhage occurs.  \n   Reason: The guideline advises against oxytocin infusion before completion of removal due to the risk of tissue embolization, unless there is significant bleeding requiring expedited surgical management.  \n\n3. **Improved patient advice** - Explicitly counsel the patient on the need for **reliable contraception** during follow-up and the recommended interval before attempting another pregnancy.  \n   Reason: The guideline emphasizes avoiding pregnancy until hCG levels normalize (usually 6 months for molar pregnancy without GTN, 1 year if chemotherapy was required).  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Confirm whether the patient was referred to a **regional trophoblastic screening center** (mentioned in the note, but ensure documentation of referral completion).  \n   Reason: The guideline mandates registration and follow-up at a GTD center for all molar pregnancies.  \n\n2. **Improved patient advice** - Provide written information on **support groups and GTD resources** for psychological support.  \n   Reason: The guideline highlights the importance of support for women and families affected by GTD.  \n\n3. **Different management plan** - Consider **ultrasound guidance** during suction curettage to minimize perforation risk and ensure complete evacuation.  \n   Reason: The guideline suggests ultrasound guidance may improve safety and completeness of molar pregnancy removal.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document whether **chest X-ray findings** were reviewed for possible metastases (already done in the note, but ensure formal reporting).  \n   Reason: The guideline notes that rare cases may present with pulmonary metastases (though this patient’s CXR was clear).  \n\n2. **Improved patient advice** - Advise the patient to report any **new symptoms (e.g., dyspnea, hemoptysis, seizures)** immediately.  \n   Reason: The guideline mentions that metastatic GTN can present with these symptoms, though they are rare.  \n\n### Unimportant Recommendations  \n1. **Additional information needed** - Consider adding a note about **thyroid function monitoring post-evacuation**, as gestational thyrotoxicosis typically resolves after molar removal.  \n   Reason: While not explicitly required by the guideline, it may help in comprehensive follow-up.  \n\n### Summary of Key Missing Elements:\n- **Anti-D prophylaxis** (if applicable)  \n- **Avoidance of pre-evacuation oxytocin** unless hemorrhage occurs  \n- **Explicit contraception counseling**  \n- **Ultrasound guidance during evacuation** (if not already used)  \n\nThe note is **largely compliant** with the guideline but could be strengthened in these areas. Would you like any further refinements?\n\n### GP004 Diagnosis and Management of Gestational Trophoblastic Disease (GTD)\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document whether a P1 form (histological assessment of Products of conception) was completed prior to surgical evacuation, as this is mandatory per the guideline.  \n   Reason: Guideline section 5.3 states this is required for all evacuations to exclude trophoblastic disease.  \n\n2. **Different management plan** - Ensure the surgical evacuation is performed at the PRH site (not Lewes Victoria) as specified in the guideline.  \n   Reason: Guideline section 6.1 specifies the procedure location for suspected molar pregnancies.  \n\n3. **Improved patient advice** - Explicitly document counseling about the prohibition of intrauterine contraceptive devices (IUCDs) until hCG normalizes and the preference for barrier methods.  \n   Reason: Guideline section 8.3 and 8.6 emphasize this contraceptive advice.  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document whether Anti-D prophylaxis was given (though not required for confirmed complete mole, per guideline section 6.7).  \n   Reason: Guideline section 6.6-6.7 clarifies Anti-D requirements based on mole type.  \n\n2. **Improved patient advice** - Include specific counseling about the 1/80 risk of recurrent molar pregnancy and the need for early viability scans in future pregnancies.  \n   Reason: Guideline sections 9.1 and 8.7 highlight these points for patient awareness.  \n\n3. **Different management plan** - Avoid oxytocic infusion prior to evacuation completion unless life-threatening bleeding occurs.  \n   Reason: Guideline section 6.4 advises against routine use of oxytocics.  \n\n### Less Important Recommendations\n1. **Additional information needed** - Note whether the EPU nurse provided the GTD leaflet and confirmed referral to Charing Cross Hospital.  \n   Reason: Guideline section 7.1-7.2 outlines post-diagnosis communication steps.  \n\n2. **Improved patient advice** - Mention the option to continue oral contraception if already started (with caveats).  \n   Reason: Guideline section 8.5 addresses this scenario.  \n\n### Unimportant Recommendations\n1. **Additional information needed** - Consider documenting whether cervical preparation was used immediately prior to evacuation (though not critical if prolonged preparation was avoided).  \n   Reason: Guideline section 6.2 mentions this as safe but not mandatory.  \n\n2. **Improved patient advice** - Reiterate the excellent prognosis (98-100% cure rate) during counseling, though this is already implied in the note.  \n   Reason: Guideline introduction cites this statistic for reassurance.  \n\n### Key Strengths of the Current Note:\n- Aligns well with guideline recommendations for urgent evacuation, serial β-hCG monitoring, and thyrotoxicosis management.  \n- Clearly documents critical features (e.g., ultrasound findings, β-hCG levels, thyroid dysfunction).  \n- Mentions mandatory registration with a trophoblastic screening center.  \n\nThe note is largely compliant but would benefit from explicit documentation of the P1 form, procedural location, and contraceptive counseling to fully adhere to the guideline.\n\n### CG13019 Triage of Maternity Patients Guideline\n\nSince the guideline content (CG13019 Triage of Maternity Patients Guideline) is not available for reference, I cannot provide specific recommendations tied to that guideline. However, based on standard clinical practice and general guidelines for molar pregnancy management, I can provide some general recommendations for improvement:\n\n### Very Important Recommendations\n1. [Additional information needed] - Document whether the patient has been screened for trophoblastic disease risk factors (e.g., prior molar pregnancy, maternal age >35 or <20, Asian ethnicity).\n   Reason: Risk factor assessment is critical for prognosis and follow-up planning in molar pregnancies.\n\n2. [Different management plan] - Consider adding methotrexate prophylaxis for high-risk complete moles (based on hCG >100,000 mIU/mL and uterine size > dates).\n   Reason: High-risk moles may benefit from prophylactic chemotherapy to prevent persistent trophoblastic disease.\n\n### Somewhat Important Recommendations\n1. [Improved patient advice] - Provide written information about molar pregnancy and the importance of follow-up, including specific warning signs of complications (persistent bleeding, respiratory symptoms, abdominal pain).\n   Reason: Patient education improves compliance with long-term monitoring requirements.\n\n2. [Additional information needed] - Document whether Rh status was checked and if Rhogam was given if patient is Rh-negative.\n   Reason: Rh sensitization prevention is important after uterine evacuation procedures.\n\n### Less Important Recommendations\n1. [Additional information needed] - Consider adding baseline liver/kidney function tests prior to potential chemotherapy.\n   Reason: Important baseline if patient develops persistent trophoblastic disease requiring treatment.\n\n2. [Improved patient advice] - Discuss fertility implications and optimal timing for future pregnancies.\n   Reason: While prognosis is excellent, patients benefit from clear conception planning guidance.\n\n### Unimportant Recommendations\n1. [Improved patient advice] - Consider providing contact information for support groups for molar pregnancy.\n   Reason: While not medically essential, psychosocial support can be valuable.\n\nWithout access to the specific CG13019 guideline content, I cannot confirm whether these recommendations align with that particular protocol. The note appears comprehensive overall, with appropriate urgent management and follow-up planning for this high-risk molar pregnancy case.\n\n### CG21009 Maternity Fluid Management as an In-patient or in Labour\n\nHere is the analysis of the clinical note against the CG21009 Maternity Fluid Management guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document current serum sodium level and trends\nReason: Guideline requires sodium monitoring for patients with >1500ml positive fluid balance or suspected hyponatremia (Section 9.1). This patient has significant fluid losses/dehydration and is at high risk for electrolyte imbalance.\n\n2. **Different management plan** - Implement formal fluid balance monitoring with hourly intake/output recording\nReason: Guideline states fluid balance monitoring is mandatory for hyperemesis patients (Section 4.0 Indications). Current note doesn't document specific fluid intake/output volumes.\n\n3. **Different management plan** - Consider sodium monitoring pathway given severe dehydration/hyperemesis\nReason: Guideline recommends Peripartum Sodium Monitoring Pathway for patients at risk of hyponatremia (Appendix 2). This patient has multiple risk factors including hyperemesis and significant fluid imbalance.\n\n### Somewhat Important Recommendations\n1. **Improved patient advice** - Counsel patient about appropriate fluid intake (isotonic drinks rather than water)\nReason: Guideline recommends against excessive water intake and suggests isotonic drinks (Section 7.0). Important for post-op recovery and prevention of recurrent hyponatremia.\n\n2. **Additional information needed** - Document urine output volume and characteristics\nReason: Guideline requires measurement and recording of all fluid losses (Section 8.2). Important for assessing degree of dehydration and renal function.\n\n3. **Different management plan** - Consider specific IV fluid regimen with electrolyte monitoring\nReason: Guideline emphasizes careful IV fluid management to prevent hyponatremia (Section 8.2). Current plan mentions IV fluids but doesn't specify type/rate.\n\n### Less Important Recommendations\n1. **Additional information needed** - Document baseline weight for fluid balance calculations\nReason: Guideline recommends accurate weight documentation for fluid management (implied in Section 4.0). Helps assess degree of dehydration.\n\n2. **Improved patient advice** - Provide written information about fluid balance importance\nReason: Guideline states importance of explaining fluid balance to patients (Section 8.1). Would improve patient understanding during recovery.\n\n### Unimportant Recommendations\n1. **Additional information needed** - Consider documenting fluid balance totals on transfer\nReason: Guideline recommends recording cumulative balance before transfers (Section 12.0). Minor point for continuity of care during this urgent case.\n\nThe most critical gaps are the lack of documented sodium levels and formal fluid balance monitoring, which are essential for patient safety given the severe hyperemesis and surgical intervention planned. The guideline emphasizes these elements to prevent hyponatremia complications.\n\n### GP010 Termination of Pregnancy\n\n### Very Important Recommendations\n1. **Additional information needed** - Document completion of Form HSA1 (Abortion Act Certificate A) with two signatures as required by law.  \n   Reason: Guideline GP010 Section 5.3 mandates completion of Form HSA1 with two qualified medical practitioners' signatures before proceeding with termination.  \n\n2. **Different management plan** - Consider medical management (mifepristone + misoprostol) as an alternative to surgical evacuation, given the high success rates (>90%) and patient acceptability.  \n   Reason: Guideline GP010 Section 7.6–7.7 recommends offering medical management for pregnancies <14 weeks unless contraindicated, with comparable efficacy to surgical evacuation.  \n\n3. **Additional information needed** - Ensure RhD status is confirmed and anti-D immunoglobulin is administered if the patient is RhD-negative.  \n   Reason: Guideline GP010 Section 5.6 requires anti-D prophylaxis for all non-sensitized RhD-negative women within 72 hours of evacuation.  \n\n### Somewhat Important Recommendations\n1. **Improved patient advice** - Counsel the patient on contraceptive options post-evacuation to prevent pregnancy during follow-up (as serial β-hCG monitoring is required).  \n   Reason: Guideline GP010 Section 8.4 emphasizes contraception counseling to avoid pregnancy during the follow-up period.  \n\n2. **Additional information needed** - Document VTE risk assessment and prophylaxis if indicated.  \n   Reason: Guideline GP010 Section 5.9 mandates VTE risk assessment for all women undergoing termination of pregnancy.  \n\n### Less Important Recommendations\n1. **Improved patient advice** - Provide written and verbal discharge instructions, including signs of complications (e.g., infection, heavy bleeding).  \n   Reason: Guideline GP010 Section 8.6 recommends clear discharge information for patient safety.  \n\n2. **Additional information needed** - Screen for Chlamydia and prescribe antibiotic prophylaxis (doxycycline + metronidazole).  \n   Reason: Guideline GP010 Section 5.7 recommends infection screening and prophylaxis for all termination procedures.  \n\n### Unimportant Recommendations\n1. **Improved patient advice** - Suggest over-the-counter ibuprofen for pain management post-procedure (if no contraindications).  \n   Reason: Guideline GP010 Section 7.19 recommends ibuprofen for pain relief but notes it is optional.  \n\n2. **Additional information needed** - Ensure histology request form (P1 consent for cremation) is completed.  \n   Reason: Guideline GP010 Section 5.3 requires this for legal documentation but does not impact immediate clinical care.  \n\n### Summary of Critical Gaps:\n- **Legal compliance**: Missing Form HSA1 certification.  \n- **Patient safety**: RhD prophylaxis and VTE assessment not explicitly documented.  \n- **Optimal care**: Medical management not discussed as an alternative despite guideline recommendations.  \n\nThese adjustments ensure adherence to protocol while maintaining patient-centered care.\n\n\n## Summary\n\nAnalyzed against 5 most relevant guidelines successfully.\n\n*Note: Found 131 relevant guidelines total, analyzed against the top 5 most relevant.*\n\n\nGuideline: Management of Gestational Trophoblastic Disease\n\n\nFull Guideline Content:\nManagement of Gestational Trophoblastic Disease\n\nHow do molar pregnancies present to the clinician?\nClinicians should be aware of the symptoms and signs of molar pregnancy. The most common presentation is irregular vaginal bleeding, a positive pregnancy test, and supporting ultrasonographic evidence. Less common presentations include hyperemesis, excessive uterine enlargement, hyperthyroidism, early-onset pre-eclampsia, and abdominal distension due to theca lutein cysts. Very rarely, women can present with haemoptysis or seizures due to metastatic disease affecting the lungs or brain.\n\nHow are molar pregnancies diagnosed?\nThe definitive diagnosis of a molar pregnancy is made by histological examination.\n\nRemoval of a molar pregnancy\nWhat is the best method for removal of a molar pregnancy?\nSuction curettage is the method of choice for removal of complete molar pregnancies. Ultrasound guidance during removal and curettage may be of use to minimize the chance of perforation and to ensure that as much tissue as possible is removed. Suction curettage is also the method of choice for removal of partial molar pregnancies except when the size of fetal parts deters the use of suction curettage and then medical removal can be used. Anti-D prophylaxis is recommended following removal of a molar pregnancy.\n\nIs it safe to prepare the cervix prior to surgical removal?\nPreparation of the cervix immediately prior to uterine removal is safe.\n\nCan oxytocic infusions be used during surgical removal?\nExcessive vaginal bleeding can be associated with surgical management of molar pregnancy, and the involvement of an experienced clinician is advised. The use of oxytocic infusion prior to completion of the removal is not recommended. If the woman is experiencing significant hemorrhage prior to or during removal, surgical removal should be expedited, and the need for oxytocin infusion weighed up against the risk of tissue embolization.\n\nIn what circumstances should a repeat surgical removal be indicated and what is the timing?\nThere is almost always a role for urgent surgical management for the woman who is experiencing heavy or persistent vaginal bleeding causing acute hemodynamic compromise, particularly in the presence of retained pregnancy tissue on ultrasound. Outside the context of acute compromise, there should be consultation with the relevant GTD referral center before performing surgical management for the second time in the same pregnancy. \n\nHistological examination of pregnancy tissue in the diagnosis of GTD\nShould pregnancy tissue from all miscarriages be examined histologically?\nThe histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia if no fetal parts are identified at any stage of the pregnancy. Women who receive care for a miscarriage should be recommended to do a urinary pregnancy test 3 weeks after miscarriage. \n\nShould pregnancy tissue be sent for examination after abortion?\nThere is no need to routinely send pregnancy tissue for histological examination following therapeutic abortion, provided that fetal parts have been identified at the time of surgical abortion or on prior ultrasound examination. Women who undergo medical abortion should be recommended to do a urinary pregnancy test 3 weeks after the procedure.\n\nHow should women with an elevated human chorionic gonadotrophin after a possible pregnancy event be managed?\nReferral to a GTD center should be considered for all women with persistently elevated human chorionic gonadotrophin (hCG) either after an ectopic pregnancy has been excluded, or after two consecutive treatments with methotrexate for a pregnancy of unknown location.\n\nWhich women should be investigated for GTN after a non-molar pregnancy?\nAny woman who develops persistent vaginal bleeding after a pregnancy event is at risk of having GTN. A urine hCG test should be performed in all cases of persistent or irregular vaginal bleeding lasting more than 8 weeks after a pregnancy event. Symptoms from metastatic disease, such as dyspnea and hemoptysis, or new onset of seizures or paralysis, can occur very rarely.\n\nBiopsy of secondary deposits in the vagina can cause major hemorrhage and is not recommended.\n\nHow should suspected ectopic molar pregnancy in women be managed?\nCases of women with ectopic pregnancy suspected to be molar in nature should be managed as any other case of ectopic pregnancy. If there is a local tissue diagnosis of ectopic molar pregnancy, the tissue should be sent to a center with appropriate expertise for pathological review.\n\nHow is twin pregnancy of a viable fetus and presumptive coexistent molar pregnancy managed?\nWomen diagnosed with a combined molar pregnancy and viable twin, or where there is diagnostic doubt, should be referred to a regional fetal medicine center and GTD center. In the situation of a twin pregnancy where there is one viable fetus and the other pregnancy is molar, the woman should be counseled about the potential increased risk of perinatal morbidity and the outcome for GTN. Prenatal invasive testing for\n\nThe incidence of GTD is associated with age at conception, being higher in the extremes of age. GTN may develop after a molar pregnancy, a non-molar pregnancy, or a live birth. Clinicians should be aware of the symptoms and signs of molar pregnancy, which include irregular vaginal bleeding, a positive pregnancy test, and supporting ultrasonographic evidence. The definitive diagnosis of a molar pregnancy is made by histological examination. Suction curettage is the method of choice for removal of complete molar pregnancies. Preparation of the cervix prior to uterine removal is safe. Repeat surgical removal may be indicated in cases of heavy or persistent vaginal bleeding causing acute hemodynamic compromise. The histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia.\n\n- Pregnancy tissue does not need to be routinely sent for histological examination after therapeutic abortion if fetal parts have been identified.\n- Women who undergo medical abortion should do a urinary pregnancy test 3 weeks after the procedure.\n- Referral to a GTD center should be considered for women with persistently elevated hCG after excluding ectopic pregnancy or after two treatments with methotrexate for a pregnancy of unknown location.\n- Persistent vaginal bleeding after a pregnancy event should prompt investigation for GTN.\n- Women with suspected ectopic molar pregnancy should be managed like any other case of ectopic pregnancy.\n- Women with combined molar pregnancy and viable twin should be referred to a regional fetal medicine center and GTD center.\n- Women with PSTT or ETT should be registered and cared for within a GTD center.\n- Women with atypical PSN should have their histology reviewed centrally for further management.\n- All women diagnosed with GTD should be registered at GTD centers for follow-up.\n- Follow-up for GTD should be based on hCG levels and may include chemotherapy.\n- Women with GTN may be treated with single-agent or multi-agent chemotherapy based on the FIGO scoring system.\n- Surgery may be considered for PSTT and ETT as they are less sensitive to chemotherapy.\n- The recommended interval between a complete or partial molar pregnancy and trying for another pregnancy should be followed.\n\nWomen following a successful pregnancy after a previous molar pregnancy are advised not to conceive until their follow-up is complete. Chemotherapy recipients are advised to wait 1 year before conceiving. Women who have a pregnancy after a molar pregnancy that did not require treatment for GTN do not need to send a post-pregnancy hCG sample. The risk of another molar pregnancy is low, and women are not at increased risk of maternal complications. However, women exposed to a molar pregnancy prior to the index birth have an increased risk of preterm birth, large-for-gestational-age birth, and stillbirth. The long-term outcome for women treated for GTN is generally excellent, with a high cure rate and successful pregnancies achieved in about 80% of cases. Women should be cautious about premature menopause after treatment with combination agent chemotherapy. It is important to avoid pregnancy until hCG levels return to normal, and contraception guidance can be found through the Faculty of Sexual and Reproductive Health. Exogenous estrogens and fertility drugs may be used after hCG levels normalize. Hormone replacement therapy is safe to use after GTD. Support is available for women and families affected by GTD. Treatment centres are recommended for GTD care. Further research is needed on predicting molar pregnancy outcomes, refining chemotherapy resistance predictions, and managing multi-relapsed disease. Support groups and useful links are provided for additional information.\n\n13. Routine histopathologic analysis of product of conception following first-trimester spontaneous miscarriages.\n14. Sonographic diagnosis of partial versus complete molar pregnancy.\n15. New insights in the pathophysiology of complete hydatidiform mole.\n16. The accuracy of first trimester ultrasound in the diagnosis of hydatidiform mole.\n17. Sonographic diagnosis of partial hydatidiform mole.\n18. Sonographic appearance of first trimester complete hydatidiform moles.\n19. Ultrasound diagnosis of molar pregnancy.\n20. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.\n21. Changes in clinical presentation of postterm choriocarcinoma at the New England Trophoblast Center in recent years.\n22. The pathology of gestational trophoblastic disease: recent advances.\n\nManagement guidelines should be evaluated with reference to individual patient needs, resources, and limitations unique to the institution and local populations. Areas of clinical uncertainty may require further research. The evidence used in this guideline was graded using a standardized scheme. Recommendations were formulated based on the quality of evidence. Good Practice Points and Expert Opinion were also considered in developing the guidelines. It is important to note that these guidelines are educational tools and not prescriptive directions for management. Local deviations from the guidelines should be documented in the patient's case notes.\n\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the guideline using quotation marks (e.g., \"According to the guideline: 'All women should receive screening for...'\")\n- Reference specific guideline recommendations or requirements\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Prioritize suggestions based on clinical importance and appropriateness\n- If no clinically appropriate suggestions can be made, return {\"suggestions\": []}\n- When in doubt about appropriateness, err on the side of NOT making the suggestion",
    "transcript_length": 2465,
    "analysis_length": 15542,
    "guideline_id": "bjog-2020-management-of-gestational-trophoblastic-disease-pdf",
    "guideline_title": "Management of Gestational Trophoblastic Disease"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: Anti-D prophylaxis documentation\",\n      \"suggestedText\": \"Administer Anti-D immunoglobulin if patient is Rh-negative, as per guideline recommendation for molar pregnancy management\",\n      \"context\": \"The guideline states: 'Anti-D prophylaxis is recommended following removal of a molar pregnancy.' This is critical for Rh-negative patients to prevent sensitization in future pregnancies. Given the patient's vaginal bleeding and planned surgical evacuation, this intervention is clinically indicated.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Gap: no documentation of oxytocic avoidance\",\n      \"suggestedText\": \"Explicitly document avoidance of oxytocic infusion prior to completion of evacuation unless significant hemorrhage occurs\",\n      \"context\": \"Guideline states: 'The use of oxytocic infusion prior to completion of the removal is not recommended.' This is particularly important in molar pregnancies due to risk of tissue embolization. The recommendation is appropriate given this patient's complete mole diagnosis and planned surgical evacuation.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Propranolol considered for thyrotoxicosis symptoms\",\n      \"suggestedText\": \"Initiate propranolol for symptomatic control of gestational thyrotoxicosis (TSH <0.1, FT4 28 pmol/L)\",\n      \"context\": \"The guideline notes hyperthyroidism can occur with molar pregnancies due to hCG stimulation. Given this patient's biochemical thyrotoxicosis and tachycardia (HR 102), beta-blockade is clinically indicated to reduce cardiovascular risks during surgery.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Presentation section\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: formal fluid balance monitoring documentation\",\n      \"suggestedText\": \"Implement strict fluid balance monitoring with hourly intake/output recording and daily weights\",\n      \"context\": \"Given the patient's severe hyperemesis (15-20 vomits/day), 6kg weight loss, and clinical dehydration, formal fluid monitoring is essential. The fluid management guideline specifically recommends this for hyperemesis patients to prevent complications.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"CG21009 Maternity Fluid Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Patient counseled regarding excellent prognosis with appropriate follow-up and monitoring\",\n      \"suggestedText\": \"Provide written counseling including: 1) Contraception requirements (avoid IUCDs until hCG normalizes), 2) 6-month pregnancy avoidance, 3) 1/80 recurrence risk, 4) Early scan in future pregnancies\",\n      \"context\": \"Guideline states: 'The recommended interval between a complete or partial molar pregnancy and trying for another pregnancy should be followed.' Detailed counseling is crucial given this patient's desire for future pregnancies. The specific points address key guideline recommendations for post-molar care.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Management of GTD - Follow-up section\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Surgical evacuation arranged urgently via suction curettage under general anesthetic\",\n      \"suggestedText\": \"Perform suction curettage with ultrasound guidance under general anesthetic\",\n      \"context\": \"Guideline recommends: 'Ultrasound guidance during removal and curettage may be of use to minimize the chance of perforation.' Given the uterine size discrepancy (16-week size at 12 weeks) and complete mole diagnosis, ultrasound guidance would enhance safety for this high-risk evacuation.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Missing: P1 form documentation\",\n      \"suggestedText\": \"Complete mandatory P1 form for histological assessment of products of conception\",\n      \"context\": \"Guideline states: 'The histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia.' This is legally required and essential for definitive diagnosis in this suspected molar pregnancy case.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"GP010 Termination of Pregnancy\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"IV fluid resuscitation commenced\",\n      \"suggestedText\": \"Initiate IV normal saline with strict electrolyte monitoring (especially sodium)\",\n      \"context\": \"Fluid management guideline recommends sodium monitoring for dehydrated hyperemesis patients. Given this patient's severe fluid losses and planned surgery, electrolyte monitoring is critical to prevent hyponatremia complications.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"CG21009 Maternity Fluid Management\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-23T20-30-23",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nSITUATION: 25-year-old G1P0 at 12+3 weeks gestation presenting with excessive nausea, vomiting, and suspected molar pregnancy\\n\\nBACKGROUND: Miss Adams has experienced severe hyperemesis since 8 weeks gestation, significantly worse than typical morning sickness described by friends. She reports vomiting 15-20 times daily, unable to keep down solid food for 2 weeks, and has lost 6kg since pregnancy confirmation. She also noticed vaginal spotting for 3 days, initially light pink but now brown discharge. Her symptoms seem disproportionately severe for gestational age. Last menstrual period was 13 weeks ago, home pregnancy tests have been consistently strongly positive. No previous pregnancies, conceived naturally after 4 months of trying. Family history includes thyroid disease (maternal). She appears significantly dehydrated and has been unable to work for 1 week due to severity of symptoms.\\n\\nASSESSMENT: Patient appears dehydrated and unwell, with obvious weight loss. Vital signs: BP 108/68 mmHg, HR 102 bpm, temp 36.9°C. Weight 52kg (down from 58kg at GP booking). Thyrotoxic signs present: mild tremor, warm skin, tachycardia. Abdominal examination reveals uterine size larger than expected for dates (approximately 16-week size). Speculum shows brown discharge from cervical os, no active bleeding. Transvaginal ultrasound demonstrates characteristic 'snowstorm' appearance with multiple cystic spaces throughout uterine cavity, no fetal pole visible. Quantitative β-hCG markedly elevated at 186,000 mIU/mL (much higher than expected for gestational age). Thyroid function tests show suppressed TSH <0.1 mU/L, elevated free T4 28 pmol/L indicating gestational thyrotoxicosis. Chest X-ray clear, no evidence of pulmonary metastases.\\n\\nRECOMMENDATION: Diagnosis of complete hydatidiform mole requiring urgent evacuation. Pre-operative investigations including FBC, coagulation screen, cross-match for 2 units blood. Surgical evacuation arranged urgently via suction curettage under general anesthetic. IV fluid resuscitation commenced. Antiemetics for symptom control. Propranolol considered for thyrotoxicosis symptoms. Post-evacuation histology confirmation and registration with regional trophoblastic screening center mandatory. Serial β-hCG monitoring weekly until negative then monthly for 6 months. Reliable contraception essential during follow-up period. Patient counseled regarding excellent prognosis with appropriate follow-up and monitoring.\\n\\nGuideline Analysis:\\n### Management of Gestational Trophoblastic Disease\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document whether Anti-D prophylaxis was given (if the patient is Rh-negative).  \\n   Reason: The guideline recommends Anti-D prophylaxis following removal of a molar pregnancy to prevent Rh sensitization in future pregnancies.  \\n\\n2. **Different management plan** - Ensure oxytocic infusion is **not** used prior to completion of surgical evacuation unless significant hemorrhage occurs.  \\n   Reason: The guideline advises against oxytocin infusion before completion of removal due to the risk of tissue embolization, unless there is significant bleeding requiring expedited surgical management.  \\n\\n3. **Improved patient advice** - Explicitly counsel the patient on the need for **reliable contraception** during follow-up and the recommended interval before attempting another pregnancy.  \\n   Reason: The guideline emphasizes avoiding pregnancy until hCG levels normalize (usually 6 months for molar pregnancy without GTN, 1 year if chemotherapy was required).  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Confirm whether the patient was referred to a **regional trophoblastic screening center** (mentioned in the note, but ensure documentation of referral completion).  \\n   Reason: The guideline mandates registration and follow-up at a GTD center for all molar pregnancies.  \\n\\n2. **Improved patient advice** - Provide written information on **support groups and GTD resources** for psychological support.  \\n   Reason: The guideline highlights the importance of support for women and families affected by GTD.  \\n\\n3. **Different management plan** - Consider **ultrasound guidance** during suction curettage to minimize perforation risk and ensure complete evacuation.  \\n   Reason: The guideline suggests ultrasound guidance may improve safety and completeness of molar pregnancy removal.  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Document whether **chest X-ray findings** were reviewed for possible metastases (already done in the note, but ensure formal reporting).  \\n   Reason: The guideline notes that rare cases may present with pulmonary metastases (though this patient’s CXR was clear).  \\n\\n2. **Improved patient advice** - Advise the patient to report any **new symptoms (e.g., dyspnea, hemoptysis, seizures)** immediately.  \\n   Reason: The guideline mentions that metastatic GTN can present with these symptoms, though they are rare.  \\n\\n### Unimportant Recommendations  \\n1. **Additional information needed** - Consider adding a note about **thyroid function monitoring post-evacuation**, as gestational thyrotoxicosis typically resolves after molar removal.  \\n   Reason: While not explicitly required by the guideline, it may help in comprehensive follow-up.  \\n\\n### Summary of Key Missing Elements:\\n- **Anti-D prophylaxis** (if applicable)  \\n- **Avoidance of pre-evacuation oxytocin** unless hemorrhage occurs  \\n- **Explicit contraception counseling**  \\n- **Ultrasound guidance during evacuation** (if not already used)  \\n\\nThe note is **largely compliant** with the guideline but could be strengthened in these areas. Would you like any further refinements?\\n\\n### GP004 Diagnosis and Management of Gestational Trophoblastic Disease (GTD)\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document whether a P1 form (histological assessment of Products of conception) was completed prior to surgical evacuation, as this is mandatory per the guideline.  \\n   Reason: Guideline section 5.3 states this is required for all evacuations to exclude trophoblastic disease.  \\n\\n2. **Different management plan** - Ensure the surgical evacuation is performed at the PRH site (not Lewes Victoria) as specified in the guideline.  \\n   Reason: Guideline section 6.1 specifies the procedure location for suspected molar pregnancies.  \\n\\n3. **Improved patient advice** - Explicitly document counseling about the prohibition of intrauterine contraceptive devices (IUCDs) until hCG normalizes and the preference for barrier methods.  \\n   Reason: Guideline section 8.3 and 8.6 emphasize this contraceptive advice.  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - Document whether Anti-D prophylaxis was given (though not required for confirmed complete mole, per guideline section 6.7).  \\n   Reason: Guideline section 6.6-6.7 clarifies Anti-D requirements based on mole type.  \\n\\n2. **Improved patient advice** - Include specific counseling about the 1/80 risk of recurrent molar pregnancy and the need for early viability scans in future pregnancies.  \\n   Reason: Guideline sections 9.1 and 8.7 highlight these points for patient awareness.  \\n\\n3. **Different management plan** - Avoid oxytocic infusion prior to evacuation completion unless life-threatening bleeding occurs.  \\n   Reason: Guideline section 6.4 advises against routine use of oxytocics.  \\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Note whether the EPU nurse provided the GTD leaflet and confirmed referral to Charing Cross Hospital.  \\n   Reason: Guideline section 7.1-7.2 outlines post-diagnosis communication steps.  \\n\\n2. **Improved patient advice** - Mention the option to continue oral contraception if already started (with caveats).  \\n   Reason: Guideline section 8.5 addresses this scenario.  \\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Consider documenting whether cervical preparation was used immediately prior to evacuation (though not critical if prolonged preparation was avoided).  \\n   Reason: Guideline section 6.2 mentions this as safe but not mandatory.  \\n\\n2. **Improved patient advice** - Reiterate the excellent prognosis (98-100% cure rate) during counseling, though this is already implied in the note.  \\n   Reason: Guideline introduction cites this statistic for reassurance.  \\n\\n### Key Strengths of the Current Note:\\n- Aligns well with guideline recommendations for urgent evacuation, serial β-hCG monitoring, and thyrotoxicosis management.  \\n- Clearly documents critical features (e.g., ultrasound findings, β-hCG levels, thyroid dysfunction).  \\n- Mentions mandatory registration with a trophoblastic screening center.  \\n\\nThe note is largely compliant but would benefit from explicit documentation of the P1 form, procedural location, and contraceptive counseling to fully adhere to the guideline.\\n\\n### CG13019 Triage of Maternity Patients Guideline\\n\\nSince the guideline content (CG13019 Triage of Maternity Patients Guideline) is not available for reference, I cannot provide specific recommendations tied to that guideline. However, based on standard clinical practice and general guidelines for molar pregnancy management, I can provide some general recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. [Additional information needed] - Document whether the patient has been screened for trophoblastic disease risk factors (e.g., prior molar pregnancy, maternal age >35 or <20, Asian ethnicity).\\n   Reason: Risk factor assessment is critical for prognosis and follow-up planning in molar pregnancies.\\n\\n2. [Different management plan] - Consider adding methotrexate prophylaxis for high-risk complete moles (based on hCG >100,000 mIU/mL and uterine size > dates).\\n   Reason: High-risk moles may benefit from prophylactic chemotherapy to prevent persistent trophoblastic disease.\\n\\n### Somewhat Important Recommendations\\n1. [Improved patient advice] - Provide written information about molar pregnancy and the importance of follow-up, including specific warning signs of complications (persistent bleeding, respiratory symptoms, abdominal pain).\\n   Reason: Patient education improves compliance with long-term monitoring requirements.\\n\\n2. [Additional information needed] - Document whether Rh status was checked and if Rhogam was given if patient is Rh-negative.\\n   Reason: Rh sensitization prevention is important after uterine evacuation procedures.\\n\\n### Less Important Recommendations\\n1. [Additional information needed] - Consider adding baseline liver/kidney function tests prior to potential chemotherapy.\\n   Reason: Important baseline if patient develops persistent trophoblastic disease requiring treatment.\\n\\n2. [Improved patient advice] - Discuss fertility implications and optimal timing for future pregnancies.\\n   Reason: While prognosis is excellent, patients benefit from clear conception planning guidance.\\n\\n### Unimportant Recommendations\\n1. [Improved patient advice] - Consider providing contact information for support groups for molar pregnancy.\\n   Reason: While not medically essential, psychosocial support can be valuable.\\n\\nWithout access to the specific CG13019 guideline content, I cannot confirm whether these recommendations align with that particular protocol. The note appears comprehensive overall, with appropriate urgent management and follow-up planning for this high-risk molar pregnancy case.\\n\\n### CG21009 Maternity Fluid Management as an In-patient or in Labour\\n\\nHere is the analysis of the clinical note against the CG21009 Maternity Fluid Management guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document current serum sodium level and trends\\nReason: Guideline requires sodium monitoring for patients with >1500ml positive fluid balance or suspected hyponatremia (Section 9.1). This patient has significant fluid losses/dehydration and is at high risk for electrolyte imbalance.\\n\\n2. **Different management plan** - Implement formal fluid balance monitoring with hourly intake/output recording\\nReason: Guideline states fluid balance monitoring is mandatory for hyperemesis patients (Section 4.0 Indications). Current note doesn't document specific fluid intake/output volumes.\\n\\n3. **Different management plan** - Consider sodium monitoring pathway given severe dehydration/hyperemesis\\nReason: Guideline recommends Peripartum Sodium Monitoring Pathway for patients at risk of hyponatremia (Appendix 2). This patient has multiple risk factors including hyperemesis and significant fluid imbalance.\\n\\n### Somewhat Important Recommendations\\n1. **Improved patient advice** - Counsel patient about appropriate fluid intake (isotonic drinks rather than water)\\nReason: Guideline recommends against excessive water intake and suggests isotonic drinks (Section 7.0). Important for post-op recovery and prevention of recurrent hyponatremia.\\n\\n2. **Additional information needed** - Document urine output volume and characteristics\\nReason: Guideline requires measurement and recording of all fluid losses (Section 8.2). Important for assessing degree of dehydration and renal function.\\n\\n3. **Different management plan** - Consider specific IV fluid regimen with electrolyte monitoring\\nReason: Guideline emphasizes careful IV fluid management to prevent hyponatremia (Section 8.2). Current plan mentions IV fluids but doesn't specify type/rate.\\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Document baseline weight for fluid balance calculations\\nReason: Guideline recommends accurate weight documentation for fluid management (implied in Section 4.0). Helps assess degree of dehydration.\\n\\n2. **Improved patient advice** - Provide written information about fluid balance importance\\nReason: Guideline states importance of explaining fluid balance to patients (Section 8.1). Would improve patient understanding during recovery.\\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Consider documenting fluid balance totals on transfer\\nReason: Guideline recommends recording cumulative balance before transfers (Section 12.0). Minor point for continuity of care during this urgent case.\\n\\nThe most critical gaps are the lack of documented sodium levels and formal fluid balance monitoring, which are essential for patient safety given the severe hyperemesis and surgical intervention planned. The guideline emphasizes these elements to prevent hyponatremia complications.\\n\\n### GP010 Termination of Pregnancy\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document completion of Form HSA1 (Abortion Act Certificate A) with two signatures as required by law.  \\n   Reason: Guideline GP010 Section 5.3 mandates completion of Form HSA1 with two qualified medical practitioners' signatures before proceeding with termination.  \\n\\n2. **Different management plan** - Consider medical management (mifepristone + misoprostol) as an alternative to surgical evacuation, given the high success rates (>90%) and patient acceptability.  \\n   Reason: Guideline GP010 Section 7.6–7.7 recommends offering medical management for pregnancies <14 weeks unless contraindicated, with comparable efficacy to surgical evacuation.  \\n\\n3. **Additional information needed** - Ensure RhD status is confirmed and anti-D immunoglobulin is administered if the patient is RhD-negative.  \\n   Reason: Guideline GP010 Section 5.6 requires anti-D prophylaxis for all non-sensitized RhD-negative women within 72 hours of evacuation.  \\n\\n### Somewhat Important Recommendations\\n1. **Improved patient advice** - Counsel the patient on contraceptive options post-evacuation to prevent pregnancy during follow-up (as serial β-hCG monitoring is required).  \\n   Reason: Guideline GP010 Section 8.4 emphasizes contraception counseling to avoid pregnancy during the follow-up period.  \\n\\n2. **Additional information needed** - Document VTE risk assessment and prophylaxis if indicated.  \\n   Reason: Guideline GP010 Section 5.9 mandates VTE risk assessment for all women undergoing termination of pregnancy.  \\n\\n### Less Important Recommendations\\n1. **Improved patient advice** - Provide written and verbal discharge instructions, including signs of complications (e.g., infection, heavy bleeding).  \\n   Reason: Guideline GP010 Section 8.6 recommends clear discharge information for patient safety.  \\n\\n2. **Additional information needed** - Screen for Chlamydia and prescribe antibiotic prophylaxis (doxycycline + metronidazole).  \\n   Reason: Guideline GP010 Section 5.7 recommends infection screening and prophylaxis for all termination procedures.  \\n\\n### Unimportant Recommendations\\n1. **Improved patient advice** - Suggest over-the-counter ibuprofen for pain management post-procedure (if no contraindications).  \\n   Reason: Guideline GP010 Section 7.19 recommends ibuprofen for pain relief but notes it is optional.  \\n\\n2. **Additional information needed** - Ensure histology request form (P1 consent for cremation) is completed.  \\n   Reason: Guideline GP010 Section 5.3 requires this for legal documentation but does not impact immediate clinical care.  \\n\\n### Summary of Critical Gaps:\\n- **Legal compliance**: Missing Form HSA1 certification.  \\n- **Patient safety**: RhD prophylaxis and VTE assessment not explicitly documented.  \\n- **Optimal care**: Medical management not discussed as an alternative despite guideline recommendations.  \\n\\nThese adjustments ensure adherence to protocol while maintaining patient-centered care.\\n\\n\\n## Summary\\n\\nAnalyzed against 5 most relevant guidelines successfully.\\n\\n*Note: Found 131 relevant guidelines total, analyzed against the top 5 most relevant.*\\n\\n\\nGuideline: Management of Gestational Trophoblastic Disease\\n\\n\\nFull Guideline Content:\\nManagement of Gestational Trophoblastic Disease\\n\\nHow do molar pregnancies present to the clinician?\\nClinicians should be aware of the symptoms and signs of molar pregnancy. The most common presentation is irregular vaginal bleeding, a positive pregnancy test, and supporting ultrasonographic evidence. Less common presentations include hyperemesis, excessive uterine enlargement, hyperthyroidism, early-onset pre-eclampsia, and abdominal distension due to theca lutein cysts. Very rarely, women can present with haemoptysis or seizures due to metastatic disease affecting the lungs or brain.\\n\\nHow are molar pregnancies diagnosed?\\nThe definitive diagnosis of a molar pregnancy is made by histological examination.\\n\\nRemoval of a molar pregnancy\\nWhat is the best method for removal of a molar pregnancy?\\nSuction curettage is the method of choice for removal of complete molar pregnancies. Ultrasound guidance during removal and curettage may be of use to minimize the chance of perforation and to ensure that as much tissue as possible is removed. Suction curettage is also the method of choice for removal of partial molar pregnancies except when the size of fetal parts deters the use of suction curettage and then medical removal can be used. Anti-D prophylaxis is recommended following removal of a molar pregnancy.\\n\\nIs it safe to prepare the cervix prior to surgical removal?\\nPreparation of the cervix immediately prior to uterine removal is safe.\\n\\nCan oxytocic infusions be used during surgical removal?\\nExcessive vaginal bleeding can be associated with surgical management of molar pregnancy, and the involvement of an experienced clinician is advised. The use of oxytocic infusion prior to completion of the removal is not recommended. If the woman is experiencing significant hemorrhage prior to or during removal, surgical removal should be expedited, and the need for oxytocin infusion weighed up against the risk of tissue embolization.\\n\\nIn what circumstances should a repeat surgical removal be indicated and what is the timing?\\nThere is almost always a role for urgent surgical management for the woman who is experiencing heavy or persistent vaginal bleeding causing acute hemodynamic compromise, particularly in the presence of retained pregnancy tissue on ultrasound. Outside the context of acute compromise, there should be consultation with the relevant GTD referral center before performing surgical management for the second time in the same pregnancy. \\n\\nHistological examination of pregnancy tissue in the diagnosis of GTD\\nShould pregnancy tissue from all miscarriages be examined histologically?\\nThe histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia if no fetal parts are identified at any stage of the pregnancy. Women who receive care for a miscarriage should be recommended to do a urinary pregnancy test 3 weeks after miscarriage. \\n\\nShould pregnancy tissue be sent for examination after abortion?\\nThere is no need to routinely send pregnancy tissue for histological examination following therapeutic abortion, provided that fetal parts have been identified at the time of surgical abortion or on prior ultrasound examination. Women who undergo medical abortion should be recommended to do a urinary pregnancy test 3 weeks after the procedure.\\n\\nHow should women with an elevated human chorionic gonadotrophin after a possible pregnancy event be managed?\\nReferral to a GTD center should be considered for all women with persistently elevated human chorionic gonadotrophin (hCG) either after an ectopic pregnancy has been excluded, or after two consecutive treatments with methotrexate for a pregnancy of unknown location.\\n\\nWhich women should be investigated for GTN after a non-molar pregnancy?\\nAny woman who develops persistent vaginal bleeding after a pregnancy event is at risk of having GTN. A urine hCG test should be performed in all cases of persistent or irregular vaginal bleeding lasting more than 8 weeks after a pregnancy event. Symptoms from metastatic disease, such as dyspnea and hemoptysis, or new onset of seizures or paralysis, can occur very rarely.\\n\\nBiopsy of secondary deposits in the vagina can cause major hemorrhage and is not recommended.\\n\\nHow should suspected ectopic molar pregnancy in women be managed?\\nCases of women with ectopic pregnancy suspected to be molar in nature should be managed as any other case of ectopic pregnancy. If there is a local tissue diagnosis of ectopic molar pregnancy, the tissue should be sent to a center with appropriate expertise for pathological review.\\n\\nHow is twin pregnancy of a viable fetus and presumptive coexistent molar pregnancy managed?\\nWomen diagnosed with a combined molar pregnancy and viable twin, or where there is diagnostic doubt, should be referred to a regional fetal medicine center and GTD center. In the situation of a twin pregnancy where there is one viable fetus and the other pregnancy is molar, the woman should be counseled about the potential increased risk of perinatal morbidity and the outcome for GTN. Prenatal invasive testing for\\n\\nThe incidence of GTD is associated with age at conception, being higher in the extremes of age. GTN may develop after a molar pregnancy, a non-molar pregnancy, or a live birth. Clinicians should be aware of the symptoms and signs of molar pregnancy, which include irregular vaginal bleeding, a positive pregnancy test, and supporting ultrasonographic evidence. The definitive diagnosis of a molar pregnancy is made by histological examination. Suction curettage is the method of choice for removal of complete molar pregnancies. Preparation of the cervix prior to uterine removal is safe. Repeat surgical removal may be indicated in cases of heavy or persistent vaginal bleeding causing acute hemodynamic compromise. The histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia.\\n\\n- Pregnancy tissue does not need to be routinely sent for histological examination after therapeutic abortion if fetal parts have been identified.\\n- Women who undergo medical abortion should do a urinary pregnancy test 3 weeks after the procedure.\\n- Referral to a GTD center should be considered for women with persistently elevated hCG after excluding ectopic pregnancy or after two treatments with methotrexate for a pregnancy of unknown location.\\n- Persistent vaginal bleeding after a pregnancy event should prompt investigation for GTN.\\n- Women with suspected ectopic molar pregnancy should be managed like any other case of ectopic pregnancy.\\n- Women with combined molar pregnancy and viable twin should be referred to a regional fetal medicine center and GTD center.\\n- Women with PSTT or ETT should be registered and cared for within a GTD center.\\n- Women with atypical PSN should have their histology reviewed centrally for further management.\\n- All women diagnosed with GTD should be registered at GTD centers for follow-up.\\n- Follow-up for GTD should be based on hCG levels and may include chemotherapy.\\n- Women with GTN may be treated with single-agent or multi-agent chemotherapy based on the FIGO scoring system.\\n- Surgery may be considered for PSTT and ETT as they are less sensitive to chemotherapy.\\n- The recommended interval between a complete or partial molar pregnancy and trying for another pregnancy should be followed.\\n\\nWomen following a successful pregnancy after a previous molar pregnancy are advised not to conceive until their follow-up is complete. Chemotherapy recipients are advised to wait 1 year before conceiving. Women who have a pregnancy after a molar pregnancy that did not require treatment for GTN do not need to send a post-pregnancy hCG sample. The risk of another molar pregnancy is low, and women are not at increased risk of maternal complications. However, women exposed to a molar pregnancy prior to the index birth have an increased risk of preterm birth, large-for-gestational-age birth, and stillbirth. The long-term outcome for women treated for GTN is generally excellent, with a high cure rate and successful pregnancies achieved in about 80% of cases. Women should be cautious about premature menopause after treatment with combination agent chemotherapy. It is important to avoid pregnancy until hCG levels return to normal, and contraception guidance can be found through the Faculty of Sexual and Reproductive Health. Exogenous estrogens and fertility drugs may be used after hCG levels normalize. Hormone replacement therapy is safe to use after GTD. Support is available for women and families affected by GTD. Treatment centres are recommended for GTD care. Further research is needed on predicting molar pregnancy outcomes, refining chemotherapy resistance predictions, and managing multi-relapsed disease. Support groups and useful links are provided for additional information.\\n\\n13. Routine histopathologic analysis of product of conception following first-trimester spontaneous miscarriages.\\n14. Sonographic diagnosis of partial versus complete molar pregnancy.\\n15. New insights in the pathophysiology of complete hydatidiform mole.\\n16. The accuracy of first trimester ultrasound in the diagnosis of hydatidiform mole.\\n17. Sonographic diagnosis of partial hydatidiform mole.\\n18. Sonographic appearance of first trimester complete hydatidiform moles.\\n19. Ultrasound diagnosis of molar pregnancy.\\n20. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.\\n21. Changes in clinical presentation of postterm choriocarcinoma at the New England Trophoblast Center in recent years.\\n22. The pathology of gestational trophoblastic disease: recent advances.\\n\\nManagement guidelines should be evaluated with reference to individual patient needs, resources, and limitations unique to the institution and local populations. Areas of clinical uncertainty may require further research. The evidence used in this guideline was graded using a standardized scheme. Recommendations were formulated based on the quality of evidence. Good Practice Points and Expert Opinion were also considered in developing the guidelines. It is important to note that these guidelines are educational tools and not prescriptive directions for management. Local deviations from the guidelines should be documented in the patient's case notes.\\n\\nPlease extract actionable suggestions from this analysis and format them as specified. For each suggestion, include detailed context with relevant quoted text from the guideline to help the user understand the reasoning behind the recommendation.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guideline in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the guideline using quotation marks (e.g., \\\"According to the guideline: 'All women should receive screening for...'\\\")\\n- Reference specific guideline recommendations or requirements\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis AND clinically appropriate for the specific scenario\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Prioritize suggestions based on clinical importance and appropriateness\\n- If no clinically appropriate suggestions can be made, return {\\\"suggestions\\\": []}\\n- When in doubt about appropriateness, err on the side of NOT making the suggestion\",\n  \"transcript_length\": 2465,\n  \"analysis_length\": 15542,\n  \"guideline_id\": \"bjog-2020-management-of-gestational-trophoblastic-disease-pdf\",\n  \"guideline_title\": \"Management of Gestational Trophoblastic Disease\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Missing: Anti-D prophylaxis documentation\",\n      \"suggestedText\": \"Administer Anti-D immunoglobulin if patient is Rh-negative, as per guideline recommendation for molar pregnancy management\",\n      \"context\": \"The guideline states: 'Anti-D prophylaxis is recommended following removal of a molar pregnancy.' This is critical for Rh-negative patients to prevent sensitization in future pregnancies. Given the patient's vaginal bleeding and planned surgical evacuation, this intervention is clinically indicated.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Gap: no documentation of oxytocic avoidance\",\n      \"suggestedText\": \"Explicitly document avoidance of oxytocic infusion prior to completion of evacuation unless significant hemorrhage occurs\",\n      \"context\": \"Guideline states: 'The use of oxytocic infusion prior to completion of the removal is not recommended.' This is particularly important in molar pregnancies due to risk of tissue embolization. The recommendation is appropriate given this patient's complete mole diagnosis and planned surgical evacuation.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Propranolol considered for thyrotoxicosis symptoms\",\n      \"suggestedText\": \"Initiate propranolol for symptomatic control of gestational thyrotoxicosis (TSH <0.1, FT4 28 pmol/L)\",\n      \"context\": \"The guideline notes hyperthyroidism can occur with molar pregnancies due to hCG stimulation. Given this patient's biochemical thyrotoxicosis and tachycardia (HR 102), beta-blockade is clinically indicated to reduce cardiovascular risks during surgery.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Management of GTD - Presentation section\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: formal fluid balance monitoring documentation\",\n      \"suggestedText\": \"Implement strict fluid balance monitoring with hourly intake/output recording and daily weights\",\n      \"context\": \"Given the patient's severe hyperemesis (15-20 vomits/day), 6kg weight loss, and clinical dehydration, formal fluid monitoring is essential. The fluid management guideline specifically recommends this for hyperemesis patients to prevent complications.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"CG21009 Maternity Fluid Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Patient counseled regarding excellent prognosis with appropriate follow-up and monitoring\",\n      \"suggestedText\": \"Provide written counseling including: 1) Contraception requirements (avoid IUCDs until hCG normalizes), 2) 6-month pregnancy avoidance, 3) 1/80 recurrence risk, 4) Early scan in future pregnancies\",\n      \"context\": \"Guideline states: 'The recommended interval between a complete or partial molar pregnancy and trying for another pregnancy should be followed.' Detailed counseling is crucial given this patient's desire for future pregnancies. The specific points address key guideline recommendations for post-molar care.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Management of GTD - Follow-up section\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Surgical evacuation arranged urgently via suction curettage under general anesthetic\",\n      \"suggestedText\": \"Perform suction curettage with ultrasound guidance under general anesthetic\",\n      \"context\": \"Guideline recommends: 'Ultrasound guidance during removal and curettage may be of use to minimize the chance of perforation.' Given the uterine size discrepancy (16-week size at 12 weeks) and complete mole diagnosis, ultrasound guidance would enhance safety for this high-risk evacuation.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Management of GTD - Removal section\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Missing: P1 form documentation\",\n      \"suggestedText\": \"Complete mandatory P1 form for histological assessment of products of conception\",\n      \"context\": \"Guideline states: 'The histological assessment of material obtained from the medical or surgical management of all miscarriages is recommended to exclude trophoblastic neoplasia.' This is legally required and essential for definitive diagnosis in this suspected molar pregnancy case.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"GP010 Termination of Pregnancy\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"IV fluid resuscitation commenced\",\n      \"suggestedText\": \"Initiate IV normal saline with strict electrolyte monitoring (especially sodium)\",\n      \"context\": \"Fluid management guideline recommends sodium monitoring for dehydrated hyperemesis patients. Given this patient's severe fluid losses and planned surgery, electrolyte monitoring is critical to prevent hyponatremia complications.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"CG21009 Maternity Fluid Management\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 6256\nCompletion tokens: 1132\nTotal tokens: 7388\nEstimated cost: $0.003694",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 6256,
    "completion_tokens": 1132,
    "total_tokens": 7388,
    "estimated_cost_usd": 0.0036940000000000002
  }
}